{
  "id": 8039034,
  "title": "Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win",
  "url": "https://urgent.news/2026/09/17/roche-eyes-label-expansion-for-lunsumio-after-confirmatory-lymphoma",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T14:34:00.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/roche-eyes-label-expansion-for-lunsumio-after-confirmatory-lymphoma-trial-win/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Roche’s T cell engager Lunsumio has passed a Phase 3 trial in a slow-growing type of blood cancer, clearing the path for full approval and a broader label. Lunsumio is a bispecific antibody that targets ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}